Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.
The phase 2 MDT-BRIDGE study is investigating perioperative durvalumab plus neoadjuvant chemotherapy (AEGEAN regimen) in resectable and borderline resectable non-small-cell lung cancer and chemoradiotherapy (CRT) followed by consolidation durvalumab (PACIFIC regimen) in patients who become unresectable after neoadjuvan...